A story on Pharmalot reports a settlement of $23 million dollars against Johnson & Johnson for issues caused by their Fort Washington, Pennsylvania plant and its over-the-counter business as a whole. After practices at the Fort Washington plant resulted in numerous product recalls and a variety of quality control issues, shareholders filed a class action lawsuit over J&J’s poor managerial performance. The lawsuit alleged that management caused a decline in market share, congressional probes, and a loss of consumer confidence ...
continue reading...Johnson & Johnson Settles $23 Million Lawsuit and Looks to Reestablish OTC Business
Posted November 25, 2013 in Product News and Recalls
Judge’s Ruling Expands Number of Hip Implant Claims
Posted November 22, 2013 in Drug and Medical Device Lawsuits | Product News and Recalls
A recent order by Judge Richard Kramer of the California Superior Court in San Francisco has expanded the type of metal-on-metal implant cases that may be filed in state court. Johnson & Johnson is facing thousands of lawsuits nationwide as a result of its subsidiary DePuy Orthopaedic’s ASR XL Acetabular System hip implants. It has been estimated that 1 out of every 8 DePuy ASR hip implants will fail prematurely and require corrective surgery within 5 ...
continue reading...Johnson & Johnson Guilty Plea Helps Risperdal Lawsuits
Posted November 19, 2013 in Health | Product Liability | Product News and Recalls | Verdicts & Settlements
After a ten-year long criminal investigation, Johnson & Johnson has entered a guilty plea and will pay $2.2 billion in damages. The U.S. Department of Justice charged the company with promoting the drugs Risperdal and Invega for off-label uses (uses that were not approved by the FDA). These drugs were approved solely for the treatment of schizophrenia, but Johnson & Johnson was promoting them for non-schizophrenic patients—including children, ...
continue reading...J&J to Pay Over $2.2 Billion in False Marketing Settlement
Posted November 11, 2013 in Drug and Medical Device Lawsuits | Product News and Recalls | Verdicts & Settlements
Johnson & Johnson (J&J) and its subsidiaries have agreed to pay over $2.2 billion in criminal and civil fines arising out of false marketing claims. The company allegedly promoted off-label uses for various drugs, and provided kickbacks to doctors and pharmacists for prescribing those drugs. The drugs at issue in this suit include Risperdal, Invega (forms of antipsychotic medications), and Natrecor (heart ...
Personal Injury Attorneys Help to Save Lives: The Public Benefits of Litigation
Posted September 5, 2013 in Product Liability | Product News and Recalls
It has recently been reported that Johnson & Johnson has decided to put red warning labels on bottles of Tylenol in order to inform users of the potentially fatal risks of acetaminophen overdose. This is a testament to the usefulness of products liability litigation.
The move by Johnson & Johnson can be considered a response to a growing number of lawsuits concerning liver injuries and deaths caused by acetaminophen overdose, as well as increased FDA scrutiny and safety proposals that ...
continue reading...Johnson & Johnson Announces New Warnings For Extra Strength Tylenol
Posted September 3, 2013 in Health | Product News and Recalls
Risks of Liver Damage and Death Form Basis for Concern
Johnson & Johnson has announced that, beginning in October, bottles of Extra Strength Tylenol sold in the U.S. will be accompanied by new warnings and instructions. The warning will make it explicitly clear that the drug contains acetaminophen, a pain-relieving ingredient that is the nation’s leading cause of sudden liver failure. According to data from the Centers for Disease Control and Prevention and the Food and Drug ...
continue reading...
